-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Benzinga·04/27/2026 11:48:30
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.